Last update 04 Nov 2024
Minghui (Nanjing) Gene Biotechnology Co., Ltd.

Minghui (Nanjing) Gene Biotechnology Co., Ltd.

Private Company | Subsidiary Company|
2021|
Jiangsu Sheng, China

Overview

Tags

Hemic and Lymphatic Diseases
Neoplasms
Immune System Diseases
CAR-T

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Hemic and Lymphatic Diseases1
Neoplasms1
Immune System Diseases1
Top 5 Drug TypeCount
CAR-T1
Top 5 TargetCount
CD30(Tumor necrosis factor receptor superfamily member 8)1

Related

1
Drugs associated with Minghui (Nanjing) Gene Biotechnology Co., Ltd.
Anti CD30 CAR-T(Minghui)
Target
CD30
Mechanism
CD30 inhibitors
Active Org.
Minghui (Nanjing) Gene Biotechnology Co., Ltd.Minghui (Nanjing) Gene Biotechnology Co., Ltd.
Originator Org.
Minghui (Nanjing) Gene Biotechnology Co., Ltd.Minghui (Nanjing) Gene Biotechnology Co., Ltd.
Active Indication
CD-30 positive Lymphoma [+1]
Inactive Indication-
Drug Highest PhaseIND Approval
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Minghui (Nanjing) Gene Biotechnology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Minghui (Nanjing) Gene Biotechnology Co., Ltd.
Login to view more data
100 Deals associated with Minghui (Nanjing) Gene Biotechnology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Minghui (Nanjing) Gene Biotechnology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Approval
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Anti CD30 CAR-T(Minghui)
 ( CD30 )		CD-30 positive Lymphoma
More
IND Approval
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free